TY - T1的免疫治疗和肺toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01737-2017 VL - 51 IS - 1 SP - 1701737 AU - Louvel, Guillaume AU - Bahleda, Rastislav AU - Ammari, Samy AU - Le Péchoux, Cécile AU - Levy, Antonin AU - Massard, Christophe AU - Le Pavec, Jérôme AU - Champiat, Stéphane AU - Deutsch, Eric Y1 - 2018/01/01 UR - //www.qdcxjkg.com/content/51/1/1701737.abstract N2 - Delaunay et al. [1] presented the results of a retrospective study of 1826 cancer patients treated with immune-checkpoint inhibitors (ICIs). 3.5% of the patients developed interstitial lung diseases (ILDs). The mechanisms of this toxicity remain largely unknown [2]. The cohort was mainly composed of lung cancer patients (75%). This explains why a significant proportion of the patients (40%) with ILD had received thoracic radiotherapy. However, patients with ILD features within the initial volumes of radiotherapy were excluded from the study to dissociate cases related to radiation pneumonitis. This study is important and brings to the light key data regarding the emerging field of clinical management of adverse ICI events.Cases of radiation pneumonitis developed after concomitant checkpoint inhibitors and lung SBRT: a matter of concern? http://ow.ly/k78q30g1qDJ ER -